A recent COVID-19 vaccine trial carried out in Taiwan has found that a mix of AstraZenca and the locally developed Medigen is more effective than two doses AstraZeneca, the head of the research team said Saturday.
The trial, initiated by Chang Gung Memorial Hospital (CGMH), was conducted among 100 people aged 22-62, who were divided into two groups, with one group given two doses of the AstraZeneca vaccine, and the other a mix-and-match of AstraZeneca and Medigen, said the team leader Chen Chih-jung (???).
In the mix-and-match group, the neutralizing antibody geometric mean titers (GMTs) after 10 days were 1.8 times higher than among those who received two doses of AstraZeneca, said Chen, who heads the Molecular Infectious Diseases Research Center at the hospital's Linkou branch.
After 28 days, the level of neutralizing antibodies against COVID-19 was 1.1 times higher in the mix-and-match group than in the AztraZeneca group, he said, during the release of the trial findings at a seminar at the hospital.
The study also found that the GMTs were twice as high when the Medigen shot was given four to six weeks after the AstraZenca, compared with an eight- to 10-week interval, Chen said.
Source: Focus Taiwan News Channel